ARBUTUS BIOPHARMA CORPORATION — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-33.2% -$523K
$1M
R&D↓-43.2% -$4M
$5M
D&A↓-96.7% -$325K
$11K
Operating Income↑+59.6% +$13M
$-9M
EBITDA↑+59.0% +$12M
$-9M
Interest Expense↓-40.0% -$12K
$18K
Interest Income↓-40.1% -$587K
$877K
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income↑+60.7% +$12M
$-8M
Operating Margin↓-35.7pts
-1636.9%
Net Margin↑+9.0pts
-1463.5%
Effective Tax Rate
—
Deferred Tax Liabilities
—
ETR (Continuing Operations)
0.0%
ETR Federal Statutory↓-2.0pts
25.0%
Operating Lease Cost
—
Revenue YoY Variation↓-6.6pts
-33.2%
Income YoY Variation↑+59.1pts
59.6%
Revenue QoQ Variation↑+81.1pts
98.7%
Income QoQ Variation↓-682.6pts
-681.9%